|
시장보고서
상품코드
1762435
세계의 파브리병 치료 시장, 규모, 점유율, 산업 분석 보고서 : 투여 경로별, 치료별, 유통 채널별, 지역별 - 시장 예측(2025-2034년)Fabry Disease Treatment Market Size, Share, & Industry Analysis Report By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면, 파브리병 치료제 시장 규모는 2034년까지 53억 2,112만 달러에 달할 것으로 예측됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.
파브리병 치료제 시장은 a-갈락토시다아제 A 효소 결핍으로 인해 발생하는 희귀한 X-연쇄 리소좀 저장 장애인 파브리병의 임상 증상을 관리하도록 설계된 치료제의 개발 및 상용화에 초점을 맞추었습니다. 이 효소 결핍은 글로보트리아오실세라미드(Gb3)의 전신 축적을 유발하여 신장, 심장, 신경계와 같은 주요 장기에 점진적인 장애를 초래합니다. 이 시장은 표적 효소 보충 요법(ERT)의 발전과 잘못 접힌 효소를 안정화시키기 위한 경구용 샤페론 요법의 가용성 확대에 힘입어 성장하고 있습니다. 의료진의 인식 제고와 진단 능력 향상으로 조기 발견이 가능해져 치료 대상이 확대되고 있습니다. 희귀질환 연구에 대한 전략적 투자는 희귀질환 치료제 개발, 정밀의료 플랫폼 등 기술 혁신을 촉진하고 규제 당국의 승인을 가속화하고 있습니다. 시장 진출기업들은 차세대 치료법에 대한 중요한 추세를 반영하여 지속성 또는 치료 가능성을 제공하는 유전자치료제 파이프라인에 집중하고 있습니다.
보험 상환 체계의 개선과 바이오 제약사와 학계와의 공동 연구 이니셔티브는 차별화된 치료 솔루션을 개발할 수 있는 새로운 기회를 창출하고 있습니다. 또한, 다양한 환자군의 미충족 수요에 대응하기 위해 지연형 및 비정형 표현형에 대한 치료법 개발이 강조되고 있습니다. 시판 후 조사 및 실제 임상에서의 근거 마련을 통해 장기적인 유효성과 안전성을 모니터링하는 노력이 강화되면서 치료제 선택에 대한 신뢰도가 높아지고 있습니다. 전반적으로 시장은 높은 미충족 수요, 임상적 복잡성, 생물학적 제제와 저분자 제제 모두에서 혁신에 대한 강력한 추진력을 특징으로 하는 역동적인 상황을 반영하고 있습니다.
파브리병 치료 시장 보고서 하이라이트
투여 경로별로는 2024년 정맥 투여가 가장 큰 점유율을 차지했습니다. 정맥 투여는 파브리병 치료에서 효소대체요법(ERT)의 주요 투여 방법입니다.
2024년에는 효소대체요법(ERT) 부문이 약 60%의 점유율을 차지했으며, ERT는 아갈시다아제 알파, 베타 등의 합성 효소를 정맥으로 주입하여 Gb3의 분해를 돕고, 질병의 진행을 지연시키며, 신경통, 위장 장애, 장기 기능 장애 등의 증상을 완화하는 치료법입니다. 증상을 완화합니다.
2024년 아시아태평양의 파브리병 치료 시장은 희귀 유전질환에 대한 인식이 높아지고 진단 인프라가 확대되면서 가장 큰 점유율을 차지했습니다.
라틴아메리카의 파브리병 치료제 시장은 2025년부터 2034년까지 크게 성장할 것으로 예측됩니다. 라틴아메리카의 의료 서비스 제공업체, 정부 및 지원 단체는 조기 진단 및 치료법에 대한 접근을 우선시하고 있으며, 이는 지역 시장 확대에 박차를 가하고 있습니다.
시장 주요 기업으로는 Amicus Therapeutics, Inc., CANbridge Life Sciences Ltd., Chiesi Farmaceutici S.p.A., Idorsia Pharmaceuticals Ltd. JCR Pharmaceuticals Co., Ltd., Protalix Biotherapeutics Inc., Sangamo Therapeutics, Inc. 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 파브리병 치료 시장 인사이트
- 시장 현황
- 파브리병 치료 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
- PESTEL 분석
- 파브리병 치료 시장 동향
- 밸류체인 분석
제5장 세계의 파브리병 치료 시장 : 투여 경로별
- 주요 조사 결과
- 서론
- 정맥내 투여
- 경구 경로
제6장 세계의 파브리병 치료 시장 : 치료별
- 주요 조사 결과
- 서론
- 효소 보충 요법(ERT)
- 기질 감소 요법(SRT)
- 기타
제7장 세계의 파브리병 치료 시장 : 유통 채널별
- 주요 조사 결과
- 서론
- 병원 약국
- 소매 약국
- 온라인 약국
제8장 세계의 파브리병 치료 시장 : 지역별
- 주요 조사 결과
- 서론
- 파브리병 치료 시장 평가 : 지역, 2020년-2034년
- 북미
- 북미 : 투여 경로별, 2020-2034년
- 북미 : 치료별, 2020-2034년
- 북미 : 유통 채널별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 투여 경로별, 2020-2034년
- 유럽 : 치료별, 2020-2034년
- 유럽 : 유통 채널별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 투여 경로별, 2020-2034년
- 아시아태평양 : 치료별, 2020-2034년
- 아시아태평양 : 유통 채널별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 투여 경로별, 2020-2034년
- 중동 및 아프리카 : 치료별, 2020-2034년
- 중동 및 아프리카 : 유통 채널별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 투여 경로별, 2020-2034년
- 라틴아메리카 : 치료별, 2020-2034년
- 라틴아메리카 : 유통 채널별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- Amicus Therapeutics, Inc.
- CANbridge Life Sciences Ltd.
- Chiesi Farmaceutici S.p.A.
- Idorsia Pharmaceuticals Ltd.
- ISU ABXIS Co., Ltd.
- JCR Pharmaceuticals Co., Ltd.
- Protalix Biotherapeutics Inc.
- Sangamo Therapeutics, Inc.
- Sanofi
- Takeda Pharmaceutical
The fabry's disease treatment market size is expected to reach USD 5,321.12 million by 2034, according to a new study by Polaris Market Research. The report "Fabry's Disease Treatment Market Size, Share, & Industry Analysis Report By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The Fabry's disease treatment market focuses on the development and commercialization of therapies designed to manage the clinical manifestations of Fabry disease, a rare X-linked lysosomal storage disorder caused by a deficiency of the a-galactosidase A enzyme. This enzymatic deficit leads to the systemic accumulation of globotriaosylceramide (Gb3), resulting in progressive damage to vital organs such as the kidneys, heart, and nervous system. The market is being propelled by advances in targeted enzyme replacement therapy (ERT) and the growing availability of oral chaperone therapies that aim to stabilize the misfolded enzymes. Rising awareness among healthcare providers and improved diagnostic capabilities are contributing to earlier detection, expanding the eligible treatment population. Strategic investments in rare disease research, including orphan drug development and precision medicine platforms, are fostering innovation and accelerating regulatory approvals. Market participants are increasingly focusing on gene therapy pipelines that offer the potential for durable or curative outcomes, reflecting a key trend toward next-generation modalities.
Improved reimbursement frameworks and collaborative research initiatives between biopharmaceutical companies and academic institutions are creating new opportunities for the development of differentiated treatment solutions. There is also a rising emphasis on developing treatments tailored to late-onset and atypical phenotypes, addressing unmet needs in diverse patient subgroups. Increasing efforts to monitor long-term efficacy and safety through post-marketing surveillance and real-world evidence generation are reinforcing confidence in therapeutic choices. Overall, the market reflects a dynamic landscape marked by high unmet need, significant clinical complexity, and a robust drive toward innovation in both biologic and small-molecule therapies.
Fabry's Disease Treatment Market Report Highlights
By route of administration, in 2024, the intravenous route segment accounted for the largest share. Intravenous (IV) administration is the primary method for delivering enzyme replacement therapy (ERT) in Fabry disease treatment.
Based on therapy, in 2024, the enzyme replacement therapy (ERT) segment accounted for approximately 60% of the share. ERT involves intravenous infusions of synthetic enzymes such as agalsidase alfa or beta, which help break down Gb3, slowing disease progression and alleviating symptoms such as neuropathic pain, gastrointestinal issues, and organ dysfunction.
In 2024, the Asia Pacific Fabry's disease treatment market accounted for the largest share due to increasing awareness of rare genetic disorders and the expansion of diagnostic infrastructure in the region.
The Latin America Fabry's disease treatment market is projected to grow significantly from 2025 to 2034. Healthcare providers, governments, and advocacy groups in LATAM are prioritizing early diagnosis and access to therapies, fueling the regional market expansion.
A few global key players include Amicus Therapeutics, Inc.; CANbridge Life Sciences Ltd.; Chiesi Farmaceutici S.p.A.; Idorsia Pharmaceuticals Ltd.; ISU ABXIS Co., Ltd.; JCR Pharmaceuticals Co., Ltd.; Protalix Biotherapeutics Inc.; Sangamo Therapeutics, Inc.; Sanofi; and Takeda Pharmaceutical.
Polaris Market Research has segmented the Fabry's disease treatment market report on the basis of route of administration, therapy, distribution channel, and region:
By Route of Administration Outlook (Revenue, USD Million, 2020-2034)
Intravenous Route
Oral Route
By Therapy Outlook (Revenue, USD Million, 2020-2034)
Enzyme Replacement Therapy (ERT)
Substrate Reduction Therapy (SRT)
Others
By Distribution Channel Outlook (Revenue, USD Million, 2020-2034)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Regional Outlook (Revenue, USD Million, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of the Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Fabry's Disease Treatment Market Insights
- 4.1. Fabry's Disease Treatment Market - Market Snapshot
- 4.2. Fabry's Disease Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Personalized Medicine Adoption in Fabry Disease Care
- 4.2.1.2. Expansion of Reimbursement Policies
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Shortage of Skilled Personal
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Fabry's Disease Treatment Market Trends
- 4.6. Value Chain Analysis
5. Global Fabry's Disease Treatment Market, by Route of Administration
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 5.3. Intravenous Route
- 5.3.1. Global Fabry's Disease Treatment Market, by Intravenous Route, by Region, 2020-2034 (USD Million)
- 5.4. Oral Route
- 5.4.1. Global Fabry's Disease Treatment Market, by Oral Route, by Region, 2020-2034 (USD Million)
6. Global Fabry's Disease Treatment Market, by Therapy
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 6.3. Enzyme Replacement Therapy (ERT)
- 6.3.1. Global Fabry's Disease Treatment Market, by Enzyme Replacement Therapy (ERT), by Region, 2020-2034 (USD Million)
- 6.4. Substrate Reduction Therapy (SRT)
- 6.4.1. Global Fabry's Disease Treatment Market, by Substrate Reduction Therapy (SRT), by Region, 2020-2034 (USD Million)
- 6.5. Others
- 6.5.1. Global Fabry's Disease Treatment Market, by Others, by Region, 2020-2034 (USD Million)
7. Global Fabry's Disease Treatment Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.3. Hospital Pharmacies
- 7.3.1. Global Fabry's Disease Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Million)
- 7.4. Retail Pharmacies
- 7.4.1. Global Fabry's Disease Treatment Market, by Retail Pharmacies, by Region, 2020-2034 (USD Million)
- 7.5. Online Pharmacies
- 7.5.1. Global Fabry's Disease Treatment Market, by Online Pharmacies, by Region, 2020-2034 (USD Million)
8. Global Fabry's Disease Treatment Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Fabry's Disease Treatment Market Assessment, By Geography, 2020-2034 (USD Million)
- 8.3. Fabry's Disease Treatment Market - North America
- 8.3.1. North America: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.2. North America: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.3. North America: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.4. Fabry's Disease Treatment Market - U.S.
- 8.3.4.1. U.S.: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.4.2. U.S.: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.4.3. U.S.: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.5. Fabry's Disease Treatment Market - Canada
- 8.3.5.1. Canada: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.5.2. Canada: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.5.3. Canada: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4. Fabry's Disease Treatment Market - Europe
- 8.4.1. Europe: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.2. Europe: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.4.3. Europe: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.4. Fabry's Disease Treatment Market - UK
- 8.4.4.1. UK: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.4.2. UK: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.4.4.3. UK: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.5. Fabry's Disease Treatment Market - France
- 8.4.5.1. France: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.5.2. France: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.4.5.3. France: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.6. Fabry's Disease Treatment Market - Germany
- 8.4.6.1. Germany: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.6.2. Germany: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.4.6.3. Germany: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.7. Fabry's Disease Treatment Market - Italy
- 8.4.7.1. Italy: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.7.2. Italy: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.4.7.3. Italy: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.8. Fabry's Disease Treatment Market - Spain
- 8.4.8.1. Spain: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.8.2. Spain: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.4.8.3. Spain: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.9. Fabry's Disease Treatment Market - Netherlands
- 8.4.9.1. Netherlands: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.9.2. Netherlands: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.4.9.3. Netherlands: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.10. Fabry's Disease Treatment Market - Russia
- 8.4.10.1. Russia: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.10.2. Russia: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.4.10.3. Russia: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.4.11. Fabry's Disease Treatment Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.4.11.2. Rest of Europe: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.4.11.3. Rest of Europe: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5. Fabry's Disease Treatment Market - Asia Pacific
- 8.5.1. Asia Pacific: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.2. Asia Pacific: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.5.3. Asia Pacific: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.4. Fabry's Disease Treatment Market - China
- 8.5.4.1. China: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.4.2. China: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.5.4.3. China: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.5. Fabry's Disease Treatment Market - India
- 8.5.5.1. India: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.5.2. India: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.5.5.3. India: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.6. Fabry's Disease Treatment Market - Malaysia
- 8.5.6.1. Malaysia: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.6.2. Malaysia: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.5.6.3. Malaysia: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.7. Fabry's Disease Treatment Market - Japan
- 8.5.7.1. Japan: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.7.2. Japan: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.5.7.3. Japan: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.8. Fabry's Disease Treatment Market - Indonesia
- 8.5.8.1. Indonesia: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.8.2. Indonesia: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.5.8.3. Indonesia: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.9. Fabry's Disease Treatment Market - South Korea
- 8.5.9.1. South Korea: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.9.2. South Korea: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.5.9.3. South Korea: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.10. Fabry's Disease Treatment Market - Australia
- 8.5.10.1. Australia: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.10.2. Australia: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.5.10.3. Australia: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.5.11. Fabry's Disease Treatment Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.5.11.2. Rest of Asia Pacific: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.5.11.3. Rest of Asia Pacific: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6. Fabry's Disease Treatment Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.2. Middle East & Africa: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.6.3. Middle East & Africa: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6.4. Fabry's Disease Treatment Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.4.2. Saudi Arabia: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.6.4.3. Saudi Arabia: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6.5. Fabry's Disease Treatment Market - UAE
- 8.6.5.1. UAE: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.5.2. UAE: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.6.5.3. UAE: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6.6. Fabry's Disease Treatment Market - Israel
- 8.6.6.1. Israel: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.6.2. Israel: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.6.6.3. Israel: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6.7. Fabry's Disease Treatment Market - South Africa
- 8.6.7.1. South Africa: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.7.2. South Africa: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.6.7.3. South Africa: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.6.8. Fabry's Disease Treatment Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.6.8.2. Rest of Middle East & Africa: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.6.8.3. Rest of Middle East & Africa: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.7. Fabry's Disease Treatment Market - Latin America
- 8.7.1. Latin America: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.7.2. Latin America: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.7.3. Latin America: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.7.4. Fabry's Disease Treatment Market - Mexico
- 8.7.4.1. Mexico: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.7.4.2. Mexico: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.7.4.3. Mexico: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.7.5. Fabry's Disease Treatment Market - Brazil
- 8.7.5.1. Brazil: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.7.5.2. Brazil: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.7.5.3. Brazil: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.7.6. Fabry's Disease Treatment Market - Argentina
- 8.7.6.1. Argentina: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.7.6.2. Argentina: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.7.6.3. Argentina: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.7.7. Fabry's Disease Treatment Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Fabry's Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.7.7.2. Rest of Latin America: Fabry's Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.7.7.3. Rest of Latin America: Fabry's Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Amicus Therapeutics, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. CANbridge Life Sciences Ltd.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Chiesi Farmaceutici S.p.A.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Idorsia Pharmaceuticals Ltd.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. ISU ABXIS Co., Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. JCR Pharmaceuticals Co., Ltd.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Protalix Biotherapeutics Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Sangamo Therapeutics, Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Sanofi
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Takeda Pharmaceutical
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
